Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.66 |
| ▸ | MEN1 | O00255 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | ECE1 | P42892 | 1/20 | 0.60 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.57 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | HRH2 | P25021 | 2/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4629003 | 0.80 | MEN1 (1.00) | MAPTMEN1KMT2ANPSR1L3MBTL1 | |
| SCHEMBL4628754 | 0.80 | MEN1 (0.67) | MAPTMEN1KMT2ANPSR1L3MBTL1 | |
| SCHEMBL4628984 | 0.80 | MEN1 (0.80) | MAPTMEN1KMT2ANPSR1L3MBTL1 | |
| SCHEMBL4628471 | 0.78 | SCN5A (0.84) | SCN5ASCN2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL4628444 | 0.77 | SCN5A (0.70) | MEN1KMT2ASCN5ASCN2ASMN1; SMN2 | |
| SCHEMBL4628482 | 0.75 | KMT2A (0.66) | MAPTMEN1KMT2ANPSR1L3MBTL1 | |
| SCHEMBL4628422 | 0.74 | MAPT (0.71) | MAPTMEN1KMT2ANPSR1L3MBTL1 | |
| SCHEMBL28969157 | 0.73 | ECE1 (0.71) | MAPTMEN1KMT2AECE1SMN1; SMN2 | |
| SCHEMBL30353801 | 0.73 | ECE1 (0.71) | MAPTMEN1KMT2AECE1SMN1; SMN2 | |
| SCHEMBL2799588 | 0.73 | MC5R (0.64) | MAPTMEN1KMT2ANPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1918272-A1 | Pharmaceutically active compounds and methods of use | Wyeth a Corporation of the State of Delaware (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1032556-A4 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE INC (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1032556-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999020599-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | GBA1, CTSA, GAA | MAPT 705/4885MEN1 1819/4885KMT2A 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.